Ontology type: schema:ScholarlyArticle Open Access: True
2021-11-20
AUTHORSTak Hong Cheung, Sally Shuk Yee Cheng, Danny C. Hsu, Queenie Wing-Lei Wong, Andrew Pavelyev, Anuj Walia, Kunal Saxena, Vimalanand S. Prabhu
ABSTRACTIntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK. More... »
PAGES75
http://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x
DOIhttp://dx.doi.org/10.1186/s12962-021-00328-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1142712721
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34801050
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Economics",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Applied Economics",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People\u2019s Republic of China",
"id": "http://www.grid.ac/institutes/grid.10784.3a",
"name": [
"Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People\u2019s Republic of China"
],
"type": "Organization"
},
"familyName": "Cheung",
"givenName": "Tak Hong",
"id": "sg:person.01371611151.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371611151.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
],
"type": "Organization"
},
"familyName": "Cheng",
"givenName": "Sally Shuk Yee",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
],
"type": "Organization"
},
"familyName": "Hsu",
"givenName": "Danny C.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
],
"type": "Organization"
},
"familyName": "Wong",
"givenName": "Queenie Wing-Lei",
"id": "sg:person.01352415670.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352415670.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "HCL America, Inc., Sunnyvale, CA, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA",
"HCL America, Inc., Sunnyvale, CA, USA"
],
"type": "Organization"
},
"familyName": "Pavelyev",
"givenName": "Andrew",
"id": "sg:person.013611671644.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611671644.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.417993.1",
"name": [
"MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
],
"type": "Organization"
},
"familyName": "Walia",
"givenName": "Anuj",
"id": "sg:person.011736111537.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011736111537.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.417993.1",
"name": [
"MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
],
"type": "Organization"
},
"familyName": "Saxena",
"givenName": "Kunal",
"id": "sg:person.013153105213.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013153105213.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.417993.1",
"name": [
"MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
],
"type": "Organization"
},
"familyName": "Prabhu",
"givenName": "Vimalanand S.",
"id": "sg:person.0725134162.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725134162.11"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/1471-2334-10-272",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026945611",
"https://doi.org/10.1186/1471-2334-10-272"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12879-020-05632-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1134382708",
"https://doi.org/10.1186/s12879-020-05632-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12916-018-1118-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1105932555",
"https://doi.org/10.1186/s12916-018-1118-3"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-11-20",
"datePublishedReg": "2021-11-20",
"description": "IntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10\u201312-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13\u201318-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13\u201318\u00a0years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK.",
"genre": "article",
"id": "sg:pub.10.1186/s12962-021-00328-x",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1032048",
"issn": [
"1478-7547"
],
"name": "Cost Effectiveness and Resource Allocation",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "19"
}
],
"keywords": [
"incremental cost-effectiveness ratio",
"human papillomavirus vaccine",
"cost-effectiveness ratio",
"papillomavirus vaccine",
"vaccination program",
"lifelong vaccine protection",
"regional vaccination program",
"cervical cancer incidence",
"vaccine coverage rates",
"healthcare payer perspective",
"public health impact",
"health impacts",
"transmission dynamic model",
"maximum health benefits",
"routine vaccination",
"vaccine protection",
"incident cases",
"vaccination strategies",
"cancer incidence",
"payer perspective",
"male/female",
"ConclusionsThis analysis",
"vaccination",
"herd immunity",
"vaccine",
"coverage rate",
"HK dollars",
"adolescent females",
"health benefits",
"ceiling threshold",
"incidence",
"HK population",
"females",
"Hong Kong",
"HPV",
"ResultsCompared",
"dose",
"immunity",
"rate",
"girls",
"population",
"routines",
"program",
"impact",
"cases",
"sensitivity analysis",
"analysis",
"study",
"benefits",
"ratio",
"Kong",
"protection",
"threshold",
"time horizon",
"addition",
"strategies",
"time",
"dollars",
"model",
"results",
"catch",
"cost",
"discount rate",
"capita",
"gross domestic product",
"products",
"perspective",
"domestic product",
"horizon",
"dynamic model"
],
"name": "The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong",
"pagination": "75",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1142712721"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12962-021-00328-x"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34801050"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12962-021-00328-x",
"https://app.dimensions.ai/details/publication/pub.1142712721"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:32",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_919.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12962-021-00328-x"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'
This table displays all metadata directly associated to this object as RDF triples.
199 TRIPLES
22 PREDICATES
99 URIs
88 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s12962-021-00328-x | schema:about | anzsrc-for:14 |
2 | ″ | ″ | anzsrc-for:1402 |
3 | ″ | schema:author | N0a837aea353648ab874a147c2994c6a9 |
4 | ″ | schema:citation | sg:pub.10.1186/1471-2334-10-272 |
5 | ″ | ″ | sg:pub.10.1186/s12879-020-05632-0 |
6 | ″ | ″ | sg:pub.10.1186/s12916-018-1118-3 |
7 | ″ | schema:datePublished | 2021-11-20 |
8 | ″ | schema:datePublishedReg | 2021-11-20 |
9 | ″ | schema:description | IntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK. |
10 | ″ | schema:genre | article |
11 | ″ | schema:inLanguage | en |
12 | ″ | schema:isAccessibleForFree | true |
13 | ″ | schema:isPartOf | N782e3984e84142c189bd8223aac94131 |
14 | ″ | ″ | Nf464ec8cc007493c902c1a7381f0d1a9 |
15 | ″ | ″ | sg:journal.1032048 |
16 | ″ | schema:keywords | ConclusionsThis analysis |
17 | ″ | ″ | HK dollars |
18 | ″ | ″ | HK population |
19 | ″ | ″ | HPV |
20 | ″ | ″ | Hong Kong |
21 | ″ | ″ | Kong |
22 | ″ | ″ | ResultsCompared |
23 | ″ | ″ | addition |
24 | ″ | ″ | adolescent females |
25 | ″ | ″ | analysis |
26 | ″ | ″ | benefits |
27 | ″ | ″ | cancer incidence |
28 | ″ | ″ | capita |
29 | ″ | ″ | cases |
30 | ″ | ″ | catch |
31 | ″ | ″ | ceiling threshold |
32 | ″ | ″ | cervical cancer incidence |
33 | ″ | ″ | cost |
34 | ″ | ″ | cost-effectiveness ratio |
35 | ″ | ″ | coverage rate |
36 | ″ | ″ | discount rate |
37 | ″ | ″ | dollars |
38 | ″ | ″ | domestic product |
39 | ″ | ″ | dose |
40 | ″ | ″ | dynamic model |
41 | ″ | ″ | females |
42 | ″ | ″ | girls |
43 | ″ | ″ | gross domestic product |
44 | ″ | ″ | health benefits |
45 | ″ | ″ | health impacts |
46 | ″ | ″ | healthcare payer perspective |
47 | ″ | ″ | herd immunity |
48 | ″ | ″ | horizon |
49 | ″ | ″ | human papillomavirus vaccine |
50 | ″ | ″ | immunity |
51 | ″ | ″ | impact |
52 | ″ | ″ | incidence |
53 | ″ | ″ | incident cases |
54 | ″ | ″ | incremental cost-effectiveness ratio |
55 | ″ | ″ | lifelong vaccine protection |
56 | ″ | ″ | male/female |
57 | ″ | ″ | maximum health benefits |
58 | ″ | ″ | model |
59 | ″ | ″ | papillomavirus vaccine |
60 | ″ | ″ | payer perspective |
61 | ″ | ″ | perspective |
62 | ″ | ″ | population |
63 | ″ | ″ | products |
64 | ″ | ″ | program |
65 | ″ | ″ | protection |
66 | ″ | ″ | public health impact |
67 | ″ | ″ | rate |
68 | ″ | ″ | ratio |
69 | ″ | ″ | regional vaccination program |
70 | ″ | ″ | results |
71 | ″ | ″ | routine vaccination |
72 | ″ | ″ | routines |
73 | ″ | ″ | sensitivity analysis |
74 | ″ | ″ | strategies |
75 | ″ | ″ | study |
76 | ″ | ″ | threshold |
77 | ″ | ″ | time |
78 | ″ | ″ | time horizon |
79 | ″ | ″ | transmission dynamic model |
80 | ″ | ″ | vaccination |
81 | ″ | ″ | vaccination program |
82 | ″ | ″ | vaccination strategies |
83 | ″ | ″ | vaccine |
84 | ″ | ″ | vaccine coverage rates |
85 | ″ | ″ | vaccine protection |
86 | ″ | schema:name | The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong |
87 | ″ | schema:pagination | 75 |
88 | ″ | schema:productId | Nb9dd3c391106497392e2cdd84b0142a5 |
89 | ″ | ″ | Nc796dc8bb27444fca98df326361cd903 |
90 | ″ | ″ | Nd1af329ac1ed45e991617297fdc4b3ab |
91 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1142712721 |
92 | ″ | ″ | https://doi.org/10.1186/s12962-021-00328-x |
93 | ″ | schema:sdDatePublished | 2022-05-10T10:32 |
94 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
95 | ″ | schema:sdPublisher | N34b114a5e5c64163a51bd1883741ad8d |
96 | ″ | schema:url | https://doi.org/10.1186/s12962-021-00328-x |
97 | ″ | sgo:license | sg:explorer/license/ |
98 | ″ | sgo:sdDataset | articles |
99 | ″ | rdf:type | schema:ScholarlyArticle |
100 | N0a837aea353648ab874a147c2994c6a9 | rdf:first | sg:person.01371611151.45 |
101 | ″ | rdf:rest | N73328def999245a186e99d4718f250bb |
102 | N0e639da2d7ad4ca782d00f03f82caac0 | rdf:first | Na0b7d424b20349bd8843b16d5b1a4360 |
103 | ″ | rdf:rest | Nc3749caefa6642ff884155dca50f5146 |
104 | N34b114a5e5c64163a51bd1883741ad8d | schema:name | Springer Nature - SN SciGraph project |
105 | ″ | rdf:type | schema:Organization |
106 | N5f5452e46acf45dcb931bd259dff76e5 | rdf:first | sg:person.011736111537.43 |
107 | ″ | rdf:rest | N6557a134209c43c5b7bd8948f6f669b4 |
108 | N650d8fb4bba748639158a542528e7c9e | rdf:first | sg:person.013611671644.98 |
109 | ″ | rdf:rest | N5f5452e46acf45dcb931bd259dff76e5 |
110 | N6557a134209c43c5b7bd8948f6f669b4 | rdf:first | sg:person.013153105213.76 |
111 | ″ | rdf:rest | Nf970732d86da49f981020a32f7b888cd |
112 | N73328def999245a186e99d4718f250bb | rdf:first | Nfc392b6d977b4c4e9508600fcf74ce69 |
113 | ″ | rdf:rest | N0e639da2d7ad4ca782d00f03f82caac0 |
114 | N782e3984e84142c189bd8223aac94131 | schema:issueNumber | 1 |
115 | ″ | rdf:type | schema:PublicationIssue |
116 | Na0b7d424b20349bd8843b16d5b1a4360 | schema:affiliation | grid-institutes:None |
117 | ″ | schema:familyName | Hsu |
118 | ″ | schema:givenName | Danny C. |
119 | ″ | rdf:type | schema:Person |
120 | Nb9dd3c391106497392e2cdd84b0142a5 | schema:name | pubmed_id |
121 | ″ | schema:value | 34801050 |
122 | ″ | rdf:type | schema:PropertyValue |
123 | Nc3749caefa6642ff884155dca50f5146 | rdf:first | sg:person.01352415670.11 |
124 | ″ | rdf:rest | N650d8fb4bba748639158a542528e7c9e |
125 | Nc796dc8bb27444fca98df326361cd903 | schema:name | dimensions_id |
126 | ″ | schema:value | pub.1142712721 |
127 | ″ | rdf:type | schema:PropertyValue |
128 | Nd1af329ac1ed45e991617297fdc4b3ab | schema:name | doi |
129 | ″ | schema:value | 10.1186/s12962-021-00328-x |
130 | ″ | rdf:type | schema:PropertyValue |
131 | Nf464ec8cc007493c902c1a7381f0d1a9 | schema:volumeNumber | 19 |
132 | ″ | rdf:type | schema:PublicationVolume |
133 | Nf970732d86da49f981020a32f7b888cd | rdf:first | sg:person.0725134162.11 |
134 | ″ | rdf:rest | rdf:nil |
135 | Nfc392b6d977b4c4e9508600fcf74ce69 | schema:affiliation | grid-institutes:None |
136 | ″ | schema:familyName | Cheng |
137 | ″ | schema:givenName | Sally Shuk Yee |
138 | ″ | rdf:type | schema:Person |
139 | anzsrc-for:14 | schema:inDefinedTermSet | anzsrc-for: |
140 | ″ | schema:name | Economics |
141 | ″ | rdf:type | schema:DefinedTerm |
142 | anzsrc-for:1402 | schema:inDefinedTermSet | anzsrc-for: |
143 | ″ | schema:name | Applied Economics |
144 | ″ | rdf:type | schema:DefinedTerm |
145 | sg:journal.1032048 | schema:issn | 1478-7547 |
146 | ″ | schema:name | Cost Effectiveness and Resource Allocation |
147 | ″ | schema:publisher | Springer Nature |
148 | ″ | rdf:type | schema:Periodical |
149 | sg:person.011736111537.43 | schema:affiliation | grid-institutes:grid.417993.1 |
150 | ″ | schema:familyName | Walia |
151 | ″ | schema:givenName | Anuj |
152 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011736111537.43 |
153 | ″ | rdf:type | schema:Person |
154 | sg:person.013153105213.76 | schema:affiliation | grid-institutes:grid.417993.1 |
155 | ″ | schema:familyName | Saxena |
156 | ″ | schema:givenName | Kunal |
157 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013153105213.76 |
158 | ″ | rdf:type | schema:Person |
159 | sg:person.01352415670.11 | schema:affiliation | grid-institutes:None |
160 | ″ | schema:familyName | Wong |
161 | ″ | schema:givenName | Queenie Wing-Lei |
162 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352415670.11 |
163 | ″ | rdf:type | schema:Person |
164 | sg:person.013611671644.98 | schema:affiliation | grid-institutes:None |
165 | ″ | schema:familyName | Pavelyev |
166 | ″ | schema:givenName | Andrew |
167 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611671644.98 |
168 | ″ | rdf:type | schema:Person |
169 | sg:person.01371611151.45 | schema:affiliation | grid-institutes:grid.10784.3a |
170 | ″ | schema:familyName | Cheung |
171 | ″ | schema:givenName | Tak Hong |
172 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371611151.45 |
173 | ″ | rdf:type | schema:Person |
174 | sg:person.0725134162.11 | schema:affiliation | grid-institutes:grid.417993.1 |
175 | ″ | schema:familyName | Prabhu |
176 | ″ | schema:givenName | Vimalanand S. |
177 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725134162.11 |
178 | ″ | rdf:type | schema:Person |
179 | sg:pub.10.1186/1471-2334-10-272 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1026945611 |
180 | ″ | ″ | https://doi.org/10.1186/1471-2334-10-272 |
181 | ″ | rdf:type | schema:CreativeWork |
182 | sg:pub.10.1186/s12879-020-05632-0 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1134382708 |
183 | ″ | ″ | https://doi.org/10.1186/s12879-020-05632-0 |
184 | ″ | rdf:type | schema:CreativeWork |
185 | sg:pub.10.1186/s12916-018-1118-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1105932555 |
186 | ″ | ″ | https://doi.org/10.1186/s12916-018-1118-3 |
187 | ″ | rdf:type | schema:CreativeWork |
188 | grid-institutes:None | schema:alternateName | Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People’s Republic of China |
189 | ″ | ″ | HCL America, Inc., Sunnyvale, CA, USA |
190 | ″ | schema:name | Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People’s Republic of China |
191 | ″ | ″ | HCL America, Inc., Sunnyvale, CA, USA |
192 | ″ | ″ | MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA |
193 | ″ | rdf:type | schema:Organization |
194 | grid-institutes:grid.10784.3a | schema:alternateName | Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China |
195 | ″ | schema:name | Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China |
196 | ″ | rdf:type | schema:Organization |
197 | grid-institutes:grid.417993.1 | schema:alternateName | MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA |
198 | ″ | schema:name | MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA |
199 | ″ | rdf:type | schema:Organization |